Mortality

Global Cancer and Tumor Profiling Market Report 2022: Benefits Such as Early Treatment for Patients & Discovery of Targeted Medicines Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022 - 2:44pm

The global cancer/tumor profiling market will reach $18 billion in 2028 and register a CAGR of 10%.

Key Points: 
  • The global cancer/tumor profiling market will reach $18 billion in 2028 and register a CAGR of 10%.
  • The use of cancer/tumor profiling enables doctors to confirm the presence and locate within a patient's body where malignant cells exist.
  • By cancer type, lung cancer segment revenue is expected to grow at a faster rate over the forecast period.
  • For this report, the publisher has segmented the global cancer/tumor profiling market on the basis of cancer type, technology, biomarker type, process type, application, and region:

SeaWorld Orlando and Orange County Public Schools Celebrate 40 Years of Partnership in Conservation Education

Retrieved on: 
Tuesday, August 9, 2022 - 2:00pm

ORLANDO, Fla., Aug. 9, 2022 /PRNewswire/ -- SeaWorld Orlando today announced it is celebrating 40 years of partnership with Orange County Public Schools (OCPS) in providing hands-on environmental and conservation education. SeaWorld and OCPS together teach students about marine life, veterinary care, hydroponic gardening, beekeeping, environmental conservation and more through field trips, immersive experiences and class discussions. The continued partnership between SeaWorld and OCPS aims to inspire the next generation to care for the environment and make a difference in the natural world.

Key Points: 
  • As part of this partnership, SeaWorld works closely with Eco Club, a group of students within OCPS dedicated to environmental conservation.
  • Students in Eco Club learn about marine life, agriculture, conservation and the natural world through fun, hands-on activities centered around environmental education.
  • Eco Club continues to provide this lettuce to the manatees at SeaWorld Orlando and visits the park annually to participate in the feedings.
  • SeaWorld Entertainment, Inc. owns or licenses a portfolio of recognized brands including SeaWorld, Busch Gardens, Aquatica, Sesame Place and Sea Rescue.

U.S. Tele-Intensive Care Unit Markets 2022-2027: Favorable Healthcare Reforms for Virtual Care & Telehealth / Technology Advances in Tele-ICU / Strategic Acquisitions & Collaborations

Retrieved on: 
Tuesday, August 9, 2022 - 12:30pm

The U.S. Tele-Intensive Care Unit (ICU) market is expected to grow at a CAGR of 20.13% during 2022-2027.

Key Points: 
  • The U.S. Tele-Intensive Care Unit (ICU) market is expected to grow at a CAGR of 20.13% during 2022-2027.
  • Telemedicine was introduced in the ICU to address intensivist shortages, increasing demand for critical care services, and increasing complexity in modern ICUs.
  • In 2020, Teladoc Health, a key leader in virtual care, announced a $13.9 billion merger with Livongo.
  • The centralized Tele-Intensive Care Unit segment reported a significant share of around 54.18% in 2021.

Global Molecular Diagnostics Market Report 2022-2028: Increase in Demand for Point-of-Care and Developments by Market Players & Prevalence of Associated Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 9, 2022 - 10:58am

The "Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The market growth is mainly attributed to an increase in demand for point-of-care devices, developments by market players, and a rise in the prevalence of associated diseases.
  • However, the increasing prevalence of associated diseases is expected to limit market growth.
  • Molecular diagnostics has wide applications in various indications such as oncology, infectious diseases, genetic testing, cardiac diseases, and immune system disorders.

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

Retrieved on: 
Tuesday, August 9, 2022 - 9:47am

Additionally, Photocure received a $1 million milestone payment from Asieris related to the ongoing clinical development of Cevira.

Key Points: 
  • Additionally, Photocure received a $1 million milestone payment from Asieris related to the ongoing clinical development of Cevira.
  • APRICITY is a multicenter, prospective, double-blind, randomized controlled Phase III study further evaluating the efficacy and safety of the integrated drug-and light-delivery device Cevira in the treatment of HSIL.
  • The clinical trial was approved by the National Medical Products Administration (NMPA) in July 2020 and was conducted simultaneously at 65 sites in 8 countries including China, Germany, Hungary and the Netherlands.
  • Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the worldwide development and commercialization of Cevira in July 2019.

Photocure Partner Asieris Announces Completion of Patient Enrollment in Cevira Phase III Clinical Trial

Retrieved on: 
Tuesday, August 9, 2022 - 9:44am

Additionally, Photocure received a $1 million milestone payment from Asieris related to the ongoing clinical development of Cevira.

Key Points: 
  • Additionally, Photocure received a $1 million milestone payment from Asieris related to the ongoing clinical development of Cevira.
  • APRICITY is a multicenter, prospective, double-blind, randomized controlled Phase III study further evaluating the efficacy and safety of the integrated drug-and light-delivery device Cevira in the treatment of HSIL.
  • The clinical trial was approved by the National Medical Products Administration (NMPA) in July 2020 and was conducted simultaneously at 65 sites in 8 countries including China, Germany, Hungary and the Netherlands.
  • Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the worldwide development and commercialization of Cevira in July 2019.

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration

Retrieved on: 
Tuesday, August 9, 2022 - 5:00am

This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union.

Key Points: 
  • This certification granted by notified bodies like BSI is required for in-vitro diagnostics to continue being sold in the European Union.
  • The IVDRs extensive requirements were adopted by the European Parliament in 2017 and must now be implemented by May 26, 2022.
  • Abionic has been preparing for IVDR compliance since 2019, and chose BSI, a reputable notified body that was authorized to perform this certification process.
  • Two years after the commercial launch of its sepsis test, Abionics expansion is reaching a global scale.

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported second quarter 2022 financial results.
  • A highlight to our teams progress in 2022 is the positive safety and efficacy data from the INTEGRIS-IPF Phase 2a trial.
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Sub-lobar Surgery for Peripheral Non-small Cell Lung Cancer non-inferior to Lobectomy

Retrieved on: 
Monday, August 8, 2022 - 4:00pm

VIENNA, Aug. 8, 2022 /PRNewswire-PRWeb/ -- A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Key Points: 
  • A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • VIENNA, Aug. 8, 2022 /PRNewswire-PRWeb/ -- A large international study of patients with non-small cell lung cancer tumors that are two centimeters or less found that sub lobar surgery was non-inferior to lobectomy, according to results presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.
  • In sub-lobar resection, the surgeon removes only the tumor and a small portion of the lung compared to a lobectomy where an entire portion of the lung is removed.
  • The increased detection of small-sized peripheral non-small cell lung cancer has renewed interest in sub-lobar resection in-lieuof lobectomy, according to N.K.

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

Retrieved on: 
Monday, August 8, 2022 - 4:05pm

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers tools designed to help clinicians make changes in patient management.

Key Points: 
  • BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers tools designed to help clinicians make changes in patient management.
  • The NGAL Test is CE marked and registered in a number of countries worldwide.
  • BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA.
  • The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange.